Eledon Pharmaceuticals Announced Data For The First Three Islet Transplant Recipients Treated With An Immunosuppression Regimen That Includes Tegoprubart To Prevent Islet Transplant Rejection In Subjects With Type 1 Diabetes
Portfolio Pulse from Benzinga Newsdesk
Eledon Pharmaceuticals reported positive data for its immunosuppression regimen including tegoprubart in islet transplant recipients with Type 1 Diabetes. Two out of three subjects achieved insulin independence, with the third on track. Tegoprubart showed higher islet engraftment compared to standard care.
October 29, 2024 | 11:47 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Eledon Pharmaceuticals' new data on tegoprubart in islet transplant recipients shows promising results, with two subjects achieving insulin independence and higher islet engraftment compared to standard care.
The positive results from the use of tegoprubart in islet transplant recipients are likely to boost investor confidence in Eledon Pharmaceuticals. Achieving insulin independence and higher engraftment rates compared to standard care suggests a significant advancement in treatment, which could lead to increased interest and potential market growth for Eledon. This news is directly related to Eledon Pharmaceuticals and is highly relevant to its stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100